Pfizer   3Q Revenues: $12.4 billion (-2%) 3Q Earnings: $2.7 billion (+3%) YTD Revenues: $36.5 billion (-4%) YTD Earnings: $7.9 billion (-59%) Comments: Global Established Pharmaceutical revenues were down 6%, primarily due to multi-source generic competition for Detrol LA in the U.S., Viagra in most major European markets, as well as Aricept in Canada. Results were also impacted by ongoing termination of the Spiriva collaboration in certain countries. Global Innovative Pharmaceutical sales w...